Oncology Institute (NASDAQ:STLN) Stock Sale Disclosed by Sen. Richard Blumenthal

Senator Richard Blumenthal (Democratic-Connecticut) recently sold part of their stake in Oncology Institute, Inc. (NASDAQ:STLN). In a filing disclosed on October 26th, the Senator disclosed that they had sold between $15,001 and $50,000 in Oncology Institute stock on September 22nd.

Senator Richard Blumenthal also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/23/2026.
• Sold $1,001 – $15,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/22/2026.
• Sold $15,001 – $50,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/18/2026.
• Sold $1,001 – $15,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/18/2026.

Oncology Institute Trading Down 6.3%

Shares of Oncology Institute stock opened at $6.29 on Tuesday. The company’s 50-day simple moving average is $6.46. Oncology Institute, Inc. has a one year low of $2.32 and a one year high of $7.13. The company has a market cap of $621.70 million, a price-to-earnings ratio of -20.97 and a beta of 0.39.

Oncology Institute (NASDAQ:STLN) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.08) earnings per share (EPS) for the quarter. The business had revenue of $161.28 million during the quarter, compared to analysts’ expectations of $152.80 million. On average, analysts predict that Oncology Institute, Inc. will post -0.21 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently commented on STLN. Needham & Company LLC raised their target price on Oncology Institute from $7.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, October 14th. Weiss Ratings assumed coverage on Oncology Institute in a research note on Thursday, August 6th. They set a “sell (d-)” rating on the stock. Lake Street Capital assumed coverage on Oncology Institute in a report on Monday, July 6th. They issued a “buy” rating and a $10.00 price target on the stock. Finally, BTIG Research increased their price target on Oncology Institute from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Thursday, July 9th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Oncology Institute has an average rating of “Moderate Buy” and an average target price of $9.00.

Insider Transactions at Oncology Institute

In other news, major shareholder Jorey Chernett acquired 12,000 shares of the firm’s stock in a transaction on Friday, August 14th. The stock was purchased at an average price of $6.54 per share, for a total transaction of $78,480.00. Following the purchase, the insider owned 10,660,858 shares in the company, valued at approximately $69,722,011.32. This represents a 0.11% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Brad Hively sold 298,853 shares of Oncology Institute stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $6.51, for a total transaction of $1,945,533.03. Following the transaction, the director directly owned 411,976 shares in the company, valued at approximately $2,681,963.76. This represents a 42.04% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 4.40% of the company’s stock.

Institutional Trading of Oncology Institute

Institutional investors have recently made changes to their positions in the company. Bank of New York Mellon Corp purchased a new stake in shares of Oncology Institute in the second quarter valued at about $961,000. State Street Corp bought a new position in shares of Oncology Institute during the second quarter valued at about $8,432,000. Bank of America Corp DE bought a new position in shares of Oncology Institute during the second quarter valued at about $2,129,000. Arrowstreet Capital Limited Partnership boosted its holdings in Oncology Institute by 169.3% during the first quarter. Arrowstreet Capital Limited Partnership now owns 419,423 shares of the company’s stock worth $1,288,000 after purchasing an additional 263,699 shares during the last quarter. Finally, Cetera Investment Advisers boosted its holdings in Oncology Institute by 427.8% during the first quarter. Cetera Investment Advisers now owns 128,195 shares of the company’s stock worth $394,000 after purchasing an additional 103,908 shares during the last quarter. Institutional investors own 36.86% of the company’s stock.

About Senator Blumenthal

Richard Blumenthal (Democratic Party) is a member of the U.S. Senate from Connecticut. He assumed office on January 3, 2011. His current term ends on January 3, 2029. Blumenthal (Democratic Party, Working Families Party) ran for re-election to the U.S. Senate to represent Connecticut. He won in the general election on November 8, 2022. Before his election to the Senate, Blumenthal had served as the Connecticut Attorney General since 1991. He served in the Connecticut State Senate from 1987 to 1991 and in the Connecticut House of Representatives from 1984 to 1987. As of a 2014 analysis of multiple outside rankings, Blumenthal is one of the most reliable Democratic votes, meaning he can be considered a safe vote for the Democratic Party in Congress.

About Oncology Institute

The Oncology Institute is a value-based oncology care company focused on delivering comprehensive cancer treatment and related services through community-based care settings. Its model is designed to support patients throughout the cancer-care journey while coordinating treatment among oncologists, primary-care providers, specialists and other healthcare professionals.

The company provides medical oncology and hematology services, cancer screening and diagnosis, treatment planning, chemotherapy and other infusion therapies, supportive care, survivorship services and care-management programs.